[go: up one dir, main page]

MX2010005861A - Agonistas novedosos de los receptores de glucocorticoides. - Google Patents

Agonistas novedosos de los receptores de glucocorticoides.

Info

Publication number
MX2010005861A
MX2010005861A MX2010005861A MX2010005861A MX2010005861A MX 2010005861 A MX2010005861 A MX 2010005861A MX 2010005861 A MX2010005861 A MX 2010005861A MX 2010005861 A MX2010005861 A MX 2010005861A MX 2010005861 A MX2010005861 A MX 2010005861A
Authority
MX
Mexico
Prior art keywords
receptor agonists
glucocorticoid receptor
novel glucocorticoid
relates
novel
Prior art date
Application number
MX2010005861A
Other languages
English (en)
Inventor
Paul Alan Glossop
David Anthony Price
David Simon Millan
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010005861(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MX2010005861A publication Critical patent/MX2010005861A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a agonistas novedosos del receptor de glucocorticoides de la fórmula (I): (ver fórmula I) y a procedimientos e intermedios para su preparación. La presente invención también se refiere a composiciones farmacéuticas que contienen estos compuestos, a su combinación con otro u otros agentes terapéuticos, así como a su uso para el tratamiento de un número de enfermedades, trastornos y afecciones inflamatorios y alérgicos.
MX2010005861A 2007-11-30 2008-11-17 Agonistas novedosos de los receptores de glucocorticoides. MX2010005861A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99135407P 2007-11-30 2007-11-30
US5724108P 2008-05-30 2008-05-30
US7955508P 2008-07-10 2008-07-10
PCT/IB2008/054801 WO2009069032A2 (en) 2007-11-30 2008-11-17 Novel glucocorticoid receptor agonists

Publications (1)

Publication Number Publication Date
MX2010005861A true MX2010005861A (es) 2010-06-11

Family

ID=40427125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005861A MX2010005861A (es) 2007-11-30 2008-11-17 Agonistas novedosos de los receptores de glucocorticoides.

Country Status (32)

Country Link
US (2) US8822439B2 (es)
EP (1) EP2225256B1 (es)
JP (1) JP4686650B2 (es)
KR (1) KR101295998B1 (es)
CN (1) CN101878221B (es)
AP (1) AP2010005267A0 (es)
AR (1) AR069490A1 (es)
AU (1) AU2008331187B2 (es)
BR (1) BRPI0820447A2 (es)
CA (1) CA2706180C (es)
CL (1) CL2008003549A1 (es)
CO (1) CO6280401A2 (es)
CR (1) CR11393A (es)
DK (1) DK2225256T3 (es)
DO (1) DOP2010000161A (es)
EA (1) EA201070535A1 (es)
EC (1) ECSP10010209A (es)
ES (1) ES2399945T3 (es)
GT (1) GT201000153A (es)
IL (1) IL205356A0 (es)
MA (1) MA31867B1 (es)
MX (1) MX2010005861A (es)
NI (1) NI201000090A (es)
NZ (1) NZ585434A (es)
PA (1) PA8805801A1 (es)
PE (1) PE20091072A1 (es)
SV (1) SV2010003580A (es)
TN (1) TN2010000230A1 (es)
TW (1) TW200930378A (es)
UY (1) UY31496A1 (es)
WO (1) WO2009069032A2 (es)
ZA (1) ZA201003439B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524057B1 (en) * 2010-01-15 2016-03-30 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
TW201139369A (en) 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
BR112013022890A2 (pt) 2011-03-15 2016-09-13 Chiesi Farma Spa composto, composição farmacêutica, combinação e uso de um composto
SG193262A1 (en) * 2011-03-15 2013-10-30 Chiesi Farma Spa Isoxazolidine derivatives
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (en) 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
HK1216513A1 (zh) 2013-03-15 2016-11-18 阿普雷奇亚制药有限责任公司 包含左乙拉西坦的快速分散劑型
WO2016133967A2 (en) * 2015-02-18 2016-08-25 Parion Sciences, Inc. Sodium channel blockers for skin disorders
PL3448391T3 (pl) 2016-04-27 2024-09-16 AbbVie Manufacturing Management Unlimited Company Sposoby leczenia chorób, w których jest szkodliwa aktywność il-13, przy zastosowaniu przeciwciała anty-il-13
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (en) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
BR112020010694A2 (pt) 2017-12-01 2020-11-10 Abbvie Inc. agonista de receptor de glicocorticoides e imunoconjugados do mesmo
KR20200095493A (ko) * 2017-12-01 2020-08-10 애브비 인코포레이티드 항-cd40 항체 약물 공액체
US20210024628A1 (en) 2018-03-22 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
CN109651474A (zh) * 2019-01-20 2019-04-19 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙的新的制备方法
CN109575097A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙产品的新的制备方法
CN109734763A (zh) * 2019-01-20 2019-05-10 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙产品的制备方法
CN109575095A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙的制备方法
BR112023016448A2 (pt) 2021-03-23 2023-10-24 Lilly Co Eli Agonistas de receptor de glucocorticoide
AR125079A1 (es) * 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
TW202304464A (zh) * 2021-03-23 2023-02-01 美商美國禮來大藥廠 新穎糖皮質素受體激動劑
CN117580849A (zh) * 2021-06-24 2024-02-20 江苏先声药业有限公司 甾体类化合物、其药物组合物及其应用
WO2023245106A1 (en) * 2022-06-16 2023-12-21 Abbvie Biotherapeutics Inc. Anti-cd19 antibody drug conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
WO2004037197A2 (en) 2002-10-24 2004-05-06 Goldstein Jay A Antifungal formulations
WO2005044759A2 (en) * 2003-08-14 2005-05-19 Sun Pharmaceutical Industries Limited Acetalization process for preparation of steroid compounds
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US20050227927A1 (en) 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis

Also Published As

Publication number Publication date
MA31867B1 (fr) 2010-11-01
TN2010000230A1 (fr) 2011-11-11
WO2009069032A3 (en) 2009-08-06
SV2010003580A (es) 2011-03-23
JP2011505350A (ja) 2011-02-24
DK2225256T3 (da) 2013-03-11
IL205356A0 (en) 2010-12-30
WO2009069032A2 (en) 2009-06-04
CL2008003549A1 (es) 2009-11-20
CA2706180C (en) 2012-10-23
NZ585434A (en) 2012-06-29
CN101878221B (zh) 2014-04-02
CA2706180A1 (en) 2009-06-04
KR101295998B1 (ko) 2013-08-13
US20140336160A1 (en) 2014-11-13
ES2399945T3 (es) 2013-04-04
EA201070535A1 (ru) 2010-12-30
US8822439B2 (en) 2014-09-02
CN101878221A (zh) 2010-11-03
CR11393A (es) 2010-05-19
UY31496A1 (es) 2009-07-17
JP4686650B2 (ja) 2011-05-25
US20090227548A1 (en) 2009-09-10
NI201000090A (es) 2010-10-04
TW200930378A (en) 2009-07-16
DOP2010000161A (es) 2010-07-15
BRPI0820447A2 (pt) 2015-05-26
HK1144821A1 (en) 2011-03-11
KR20100074306A (ko) 2010-07-01
AP2010005267A0 (en) 2010-06-30
PE20091072A1 (es) 2009-07-23
CO6280401A2 (es) 2011-05-20
ZA201003439B (en) 2011-02-23
EP2225256A2 (en) 2010-09-08
ECSP10010209A (es) 2010-06-29
AU2008331187A1 (en) 2009-06-04
GT201000153A (es) 2012-04-27
AU2008331187B2 (en) 2014-04-03
AR069490A1 (es) 2010-01-27
EP2225256B1 (en) 2013-01-09
PA8805801A1 (es) 2009-07-23

Similar Documents

Publication Publication Date Title
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
MX2009013733A (es) Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1.
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
ECSP11010754A (es) Derivados de triazol útiles para el tratamiento de enfermedades
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
WO2008152093A3 (en) Diaminopyrimidines as modulators of the ep2 receptor
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
GEP201606513B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
WO2008152094A3 (en) Substituted acetamides as modulators of the ep2 receptor
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
DE602007005387D1 (de) Ptors
UA95861C2 (en) Glucocorticoid receptor agonists

Legal Events

Date Code Title Description
FG Grant or registration